Compare Crowdstrike Holdings Inc (CRWD) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Quest Diagnostics Inc — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Crowdstrike Holdings Inc is far larger — about 10.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Quest Diagnostics Inc for 56 Days on average.
| CRWD | DGX | |
|---|---|---|
Market Cap | $269.31B | $25.48B |
Volume | 9,381,560 | 941,866 |
Sector | Technology | Health |
52-Week High | $278.86 | $247.45 |
52-Week Low | $87.56 | $173.49 |
Typical Hold Time | 97 Days | 56 Days |
Enterprise Value | $265.11B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $275.04, up 3.62% today and near its all-time high, with a bullish technical signal from moving averages. The company shows strong revenue growth, reaching $3.95B in 2025, though net income remains negative at -$19.27M. Recent earnings beats and positive analyst sentiment (76% buy ratings) highlight momentum, while the stock trades at elevated valuation multiples like P/S of 49.86. Key developments include expansion into the OpenAI Marketplace and AI-driven cybersecurity demand.
Outlook: CrowdStrike's growth trajectory and AI positioning offer upside, but high valuations and profitability challenges pose risks. Analyst consensus target is $235.74, below current price, suggesting caution despite bullish sentiment. Competitive pressures and execution on net income conversion are critical for sustained gains.
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
